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OBJECTIVE: To assess glucose homeostasis and weight loss in morbidly obese patients undergoing Silastic® ring sleeve gas-
trectomy. 
METHODS: This was a prospective clinical study. Thirty-three female patients with a mean body mass index (BMI) of 42.33 ± 
1.50 kg/m2 (range: 40-45 kg/m2), a mean age of 36.7 ± 9.4 years and a mean waist circumference of 118.7 ± 5.98 cm were included 
in this study. Type 2 diabetes mellitus was observed in 11 patients (33.3%), and glucose intolerance was observed in 4 patients 
(12.1%). Mean plasma fasting glucose levels were 109.77 ± 44.19 mg/dl (75-320) in the preoperative period. All Silastic® ring 
sleeve gastrectomy procedures were performed by the same surgical team using the same anesthetic technique. The patients were 
monitored for at least 12 months after surgery. 
RESULTS: The mean weight of the patients decreased from 107.69 ± 6.57 kg to 70.52 ± 9.36 kg (p < 0.001), the mean BMI 
decreased to 27.4 ± 2.42 kg/m2 (p < 0.001), and the mean waist circumference decreased to 89.87 cm ± 6.66 (p < 0.001) in the 
postoperative period. Excess BMI loss was 86.5 ± 14.2%. Fasting glucose levels were reduced to 80.94 ± 6.3 mg/dl (p < 0.001). 
Remission of diabetes and glucose intolerance was observed in all patients. 
CONCLUSION: Silastic® ring sleeve gastrectomy was effective in promoting weight loss, waist circumference reduction and 
control of glucose homeostasis in morbidly obese patients.
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INTRODUCTION
Obesity is a multifactorial disease that affects millions 
of people worldwide. It is the main independent risk factor 
for developing type 2 diabetes mellitus (T2DM),1,2 leading 
to a condition known as diabesity.2,3 In patients with morbid 
obesity, the likelihood of developing T2DM and glucose 
intolerance (GI) is further increased.1,4
Bariatric surgery provides sustained weight loss and 
leads to well-documented remission of T2DM in obese, 
diabetic patients.5,6 Patients who undergo bariatric surgery 
have a decreased rate of long-term mortality compared to 
obese patients who do not receive bariatric surgery,7 with 
136 lives saved per 10,000 surgical procedures performed.8 
Currently, bariatric surgery is the most effective choice of 
treatment for morbidly obese patients with T2DM.9
Surgical procedures to treat morbid obesity are 
divided into two groups: gastric restrictive procedures 
and procedures that combine gastric restriction and 
malabsorption.10 The Roux-en-Y gastric bypass (RYGB) 
procedure is well-established and is the most frequent 
bariatric surgery performed,7,11 whereas sleeve gastrectomy 1094
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(SG) is an emerging restrictive procedure.12 SG can be 
performed as the first of a two-stage operation in patients at 
high risk of death13,14 or as a definitive surgical procedure.15 
It has shown good results with regard to weight loss16 and 
glycemic control in various studies.6,14,16,17 The potential 
advantages of SG include a lower probability of vitamin 
and mineral deficiencies than RYGB, access to the entire 
intestinal tract, a lack of need for a subcutaneous access 
port and a lower risk of intestinal obstruction. In addition, 
SG can be performed in patients who have inflammatory 
bowel disease or have undergone previous bowel surgery, 
and it can be easily converted into a RYGB.12,15 Both SG and 
RYGB can be performed with or without the placement of 
a Silastic® ring.18,19
Metabolic control can be achieved with gastric restrictive 
procedures such as vertical banded gastroplasty,5 adjustable 
gastric banding20 and, more recently, SG.17 However, 
previous studies have found that glucose homeostasis is 
affected by various intestinal mechanisms that are only 
altered by bariatric surgery procedures that include an 
intestinal element,21 such as RYGB.22-24 A systematic review 
showed resolution of T2DM in 76.8% of patients undergoing 
RYGB and improvement of glycemic control in 86% of 
patients.25 Of the criteria used to diagnose the metabolic 
syndrome, fasting glucose levels26 are the first to return 
to normal in patients who have undergone Silastic® ring 
sleeve gastrectomy. The achievement of normoglycemia after 
bariatric procedures results from multiple changes that occur 
postoperatively,6,27,28 such as dietary control,20,21 decreased 
plasma ghrelin levels,29,30 weight loss, reduction of body fat,6 
and the release of gastrointestinal hormones that interfere 
with the function of pancreatic β cells (incretins).23,24,31,32
The main purpose of this study was to assess weight 
loss in morbidly obese patients undergoing SRSG as well 
as to evaluate the effects of the SRSG procedure on glucose 
homeostasis.
METHODS
Study protocol
This was a prospective clinical study. It was approved by 
the Research Ethics Committee of the University Hospital 
of the Federal University of Espírito Santo, Brazil (protocol 
no. 049/06). To obtain a homogenous sample, we adopted 
the following inclusion criteria: we included female patients 
20-60 years with a BMI of 40-45 who agreed to provide 
written informed consent. The exclusion criteria included the 
following: secondary obesity, alcohol or drug use, presence 
of a severe psychiatric disorder, binge-eating disorders and 
previous stomach or bowel surgery.
Sample
Thirty-three female patients were included in the 
present study. The patients had a mean age of 36.7 ± 
9.4 years, a mean BMI of 42.33 ± 1.5 and a mean waist 
circumference of 118.7 ± 5.98 cm. The mean preoperative 
fasting glucose level of the included patients was 108.5 
± 43.76 mg/dl. The diagnoses of diabetes and GI were 
based on the criteria adopted by the Brazilian Diabetes 
Society.33 T2DM was found in 11 patients (33.3%), and 
GI was found in 4 patients (12.1%). Therefore, 45.4% of 
the morbidly obese patients analyzed in the present study 
presented with elevated fasting glucose levels. Most of 
the diabetic patients were treated with oral hypoglycemic 
agents. Assessment was performed one year (range: 12 to 
14 months) after surgery.
Surgical procedure
The surgical procedures were performed between 
December 08, 2006 and July 27, 2007 at Hospital at Hospital 
Universitário Cassiano Antonio Moraes da Universidade 
Federal do Espírito Santo (HUCAM/UFES, Cassiano 
Antonio Moraes University Hospital, Federal University 
of Espírito Santo). The procedures were performed by the 
same surgeon using similar anesthetic techniques (epidural 
anesthesia combined with general anesthesia).
Silastic® ring sleeve gastrectomy was performed as 
follows: the vessels of the greater curvature of the body 
and fundus of the stomach were ligated, and the fundus and 
part of the body of the stomach was resected using a linear 
stapler (80 mm, Tyco®). A 32-Fr tube was then used to 
calibrate the diameter of the remaining stomach and a 6.2-
cm Silastic® ring was placed around the stomach, 5.0 cm 
below the esophagogastric junction. 
The staple lines were then oversewn, and a methylene 
blue test was performed to verify that the staple line 
was secure. The patients were given a liquid diet on the 
first postoperative day and were discharged on the third 
postoperative day. They received dietary guidance and 
instructions regarding physical activities and were also 
prescribed vitamin and mineral supplements.
Assessment
Weight loss, BMI reduction and waist circumference 
reduction were assessed. The percentage of excess BMI lost 
was calculated using the following formula: excess BMI loss 
= (preoperative BMI - current BMI) ÷ (preoperative BMI 
– 25) × 100.34 Glucose homeostasis was assessed through 
the measurement of fasting plasma glucose levels and an 1095
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oral glucose tolerance test, after hipoglicemic agents were 
discontinued. 
Statistical analysis
The results of the descriptive analyses were expressed 
as means, standard deviations, medians, frequency (%), 
minimum values and maximum values. The Wilcoxon 
matched pairs test was used to analyze the differences 
between pre-treatment and post-treatment plasma glucose 
levels. The McNemar test was used to compare the rates 
of T2DM and GI pre- and post-treatment. Statistical 
significance was set at p < 0.05.
RESULTS
Although it was not the main focus of the present 
study, it was noteworthy that two patients (6%) developed 
a fistula at the staple line at the level of the cardiac notch. 
Both patients required reoperation. One patient died, and 
the other underwent total gastrectomy, which led to the 
resolution of the fistula. These patients, neither of whom 
had T2DM or GI, were excluded from the postoperative 
analysis. Therefore, a total of 31 patients were included in 
the postoperative analysis. In these 31 patients, the mean 
weight decreased from 107.69 ± 6.57 kg to 70.52 ± 9.36 kg 
(p < 0.001). BMI decreased from 42.27 ± 1.46 kg/m2 to 27.4 
± 2.42 kg/m2 (p < 0.001), a reduction of 35.18% (Figure 1). 
Waist circumference decreased from 118.42 ± 5.71 cm to 
89.87± 6.66 cm (p < 0.001) (Figure 2). The percentage of 
excess BMI loss was 86.51 ± 14.2% (46.6 – 108.5%). 
The reduction in glucose levels was also significant (p < 
0.001), with mean plasma glucose values decreasing from a 
preoperative mean of 109.77 ± 44.19 to a postoperative mean 
of 80.94 ± 6.3 mg/dl (Figure 3). This reduction was more 
marked in patients with T2DM and/or GI.
SRSG proved to be effective in promoting the resolution 
of T2DM and GI in affected patients (p < 0.001) (Figure 
4). All patients were able to discontinue the use of oral 
hypoglycemic agents, insulin, or both, during the follow-up 
period (Table 1).
Figure 1 - Body Mass Index (preoperative and postoperative)
Figure 2 - Waist circumference (preoperative and postoperative)
Figure 4 - Prevalence of T2DM and glucose intolerance
Figure 3 - Fasting plasma glucose levels (preoperative and postoperative)1096
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DISCUSSION
Obesity can cause deleterious effects on many organic 
functions and impair health and quality of life.35 The SG 
procedure is used with increasing frequency in bariatric 
surgery.12-17 However, there are few prospective clinical 
studies in the literature that compare this emerging procedure 
with the gold standard, RYGB.12,17
In the present study, SG was performed, and a Silastic® 
ring was placed around the stomach. We thus created a 
small, functional stomach, much like that created during 
traditional vertical gastroplasty. We also removed the 
principal site of ghrelin production, which gave the SRSG 
the characteristics of both bariatric and endocrine surgery.19 
The removal of the principal site of ghrelin production led to 
a decrease in ghrelin levels, adding a hormonal component 
to SRSG that other restrictive procedures lack, such as 
adjustable gastric banding.31 Some authors have reported the 
use of added restriction in SG to increase the intensity and 
duration of weight loss.19,36,37
Some researchers have reported that SG is less risky than 
RYGB.12-14 In our sample, however, serious complications 
and death occurred after SG.
We observed significant weight loss, BMI reduction, 
waist circumference reduction and excess BMI loss in 
this study. These findings are in accordance with several 
studies12,15,17 but are in disagreement with others13,14 that 
regarded SG as simply the first stage of a definitive surgery. 
The promising results of the present study are most likely 
due (at least in part) to the judicious inclusion criteria we 
chose, which excluded patients with a BMI greater than 45 
and patients who had undergone prior stomach or bowel 
surgery. 
In these patient populations, the results of bariatric 
surgery have admittedly been less effective. Other factors 
that might have contributed to the promising results of 
the present study include the calibration of the remaining 
stomach using a 32-Fr tube and the placement of a 
Silastic® ring. In other studies in which weight loss was 
less pronounced, tubes of a larger caliber were used39, and a 
Silastic® ring was not placed.13,14
Resolution of T2DM has been well-documented in 
various types of bariatric surgery.5 In two studies of patients 
undergoing SG, control of T2DM was achieved in 80% of 
patients.13,14 This remission rate was higher than the rate that 
is commonly reported for restrictive procedures like vertical 
banded gastroplasty5 and adjustable gastric banding.20 This 
rate, however, is lower than that obtained with RYGB9,26 and 
biliopancreatic diversion procedures.21
In the present study, all of the patients with T2DM or GI 
went into clinical remission, a surprising result also found 
in another study.17 Because SRSG is basically a restrictive 
procedure that does not affect incretin expression, it was 
expected that the results obtained from this procedure would 
be inferior to those obtained from procedures in which 
a duodenal switch is performed with regard to glucose 
homeostasis.23,24,27,28 In the present study, glucose levels 
might have decreased as a result of the marked weight 
loss observed in all patients, which led to increased insulin 
sensitivity and decreased leptin production, and thus to 
increased insulin secretion and remission of GI and T2DM, 
as noted in previous studies.6,39 Other hormones produced in 
adipose tissue might also have been involved in the notable 
rate of glycemic control observed in the present study.
It is notable, however, that only one patient who 
underwent surgery in the present study used insulin 
preoperatively. The other 14 patients with GI or T2DM were 
treated with oral hypoglycemic agents.
According to previous studies, remission or dietary 
control of GI/T2DM is more likely to be possible in these 
patients after bariatric surgery than patients who required 
insulin preoperatively.22,24
The greatest limitations of the present study were the 
short follow-up period and the lack of a control group for 
comparison. However, the study sample was comprised of 
patients with similar baseline characteristics, namely age, 
Table 1 - Glucose homeostasis and oral hyperglycemic agent/insulin use before and after SRSG
Glucose homeostasis Preoperative period Postoperative period
n % n %
Normal 18 54.6 31 100
Glucose intolerance 04 12.1 0 0
T2DM — diet controlled 04 12.1 0 0
T2DM — OHG 06 18.2 0 0
T2DM — OHG + Insulin 01 3 0 0
Total 33 100% 31 100%
T2DM: type 2 diabetes mellitus. GI: glucose intolerance. OHG: oral hypoglycemic agents.1097
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BMI, waist circumference and preoperative fasting glucose 
levels. The similar baselines among patients is an advantage 
for this study over previous studies in which the patient 
populations were not similar at baseline,12 and the patients 
often had BMIs of < 4012,15,17 and/or > 50.12-17
CONCLUSIONS
The surgical procedure in the present study, SRSG, 
resulted in marked weight loss, BMI reduction, waist 
circumference reduction, excess BMI loss, improved glucose 
homeostasis and remission of GI and T2DM in our study 
population. Further studies need to evaluate SRSG with a 
longer follow-up period, a control group and the inclusion 
of other variables, such as hormonal changes, to solidify 
SRSG’s standing as a bariatric surgery procedure.
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